Follow us:

Editor Details

Go Back to Editorial Board

NameHironobu Ihn
DesignationProfessor
DepartmentDermatology
CountryJapan
Address

Vice President, Kumamoto University Hospital,1-1-1 Honjo, Chuo, Kumamoto, Kumamoto Prefecture 860-8556, Japan .   


Biography :

Professionla Training and Emplyment:

2013 – present     Vice President, Kumamoto University Hospita

2005 – present     Professor & Chairman, Department of Dermatology & PlasticSurgery, Faculty Life Sciences, Kumamoto University, Kumamoto, Japan.

2005                    Associate Professor, Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. 

2001-2005    Lecturer, Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.

1997-2001           Assistant, Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.

1994-1997           Research Fellow, Division of Rheumatology & Immunology, Medical University of South Carolina, SC, USA.

1993-1994           Assistant, Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. 

1992-1993           Clinical Fellow, Department of Dermatology, Kanto Rosai Hospital, Kanagawa, Japan. 

1991-1992           Clinical Fellow, Department of Dermatology, Kousei General Hospital, Tokyo, Japan. 

1990-1991           Assistant, Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. 

Japanese Society of Dermatology, Japanese Society of Investigative Dermatology, Japanese Society of Clinical Immunology, Japanese Society of connective tissue Research, American Academy of Immunologists, American Society for Matrix Biology, Japanese Society of Allergy, Japanese Society of Rheumatology, Japanese Society of Cosmetic Dermatology, Japanese Society of Psoriasis, Japanese Society of Skin Cancer.

 

Education:

  •  1998     Ph.D.,   University of Tokyo (Thesis: The function of transcription factor Sp3 in the transcriptional regulation of the human 2(I) collagen gene)
  •   1990    M.D.,   University of Tokyo

 

 

 

List of Publications:

1.  Ihn H, Sato S, Tamaki T, Soma Y, Tsuchida T, Ishibashi Y, Takehara K.  Clinical evaluation of scleroderma spectrum disorders using a points system. Arch Dermatol Res, 284: 391-395, 1992.

2.  Ihn H, Nakamura K, Abe M, Furue M, Takehara K, Nakagawa H, Ishibashi Y. Amelanotic metastatic melanoma in a patient with oculocutaneous albinism. J Am Acad Dermatol, 28: 895-900, 1993.

3.  Sato S, Ihn H, Soma Y, Igarashi A, Tamaki T, Kikuchi K, Ishibashi Y, Takehara K.  Antihistone antibodies in patients with localized scleroderma. Arthritis Rheum, 36: 1137-1141, 1993.

4.  Sato S, Ihn H, Soma Y, Shimozuma M, Shishiba T, Takehara K.  A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies. J Rheumatol, 20: 1961-1963, 1993.

5.  Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K.  Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. Arch Dermatol, 130: 1327-1328, 1994.

6.  Ihn H, Fujimoto M, Sato S, Kikuchi K, Igarashi A, Soma Y, Takehara K.  Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. J Am Acad Dermatol, 31: 591-595, 1994

7.  Sato S, Ihn H, Kikuchi K, Takehara K.  Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum, 37: 391-394, 1994.

8.  Sato S, Fujimoto M, Ihn H, Takehara K.  Antibodies to centromere and centriole in scleroderma spectrum disorders. Dermatology, 189: 23-26, 1994.

9.  Kikuchi K, Ihn H, Sato S, Igarashi A, Soma Y, Ishibashi Y, Takehara K. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis. Arch Dermatol Res, 286:77-80, 1994.

10.  Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K.  Antigen specificity of antihistone antibodies in localized scleroderma. Arch Dermatol, 130: 1273-1277, 1994. 

11.  Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K.  Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol, 31:567-571, 1994.

12.  Kikuchi K, Sato S, Kadono T, Ihn H, Takehara K.  Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma. Arch Dermatol, 130: 1269-1272. 1994.

13. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K, Ishibashi Y. 

Demonstration of interleukin-2, interleukin-4, interleukin-6 and soluble interleukin-2 receptor in sera from patients with localized scleroderma. J Invest Dermatol, 102: 584, 1994. (abstract)

14.  Sato S, Ihn H, Soma Y, Tamaki T, Kikuchi K, Ishibashi Y, Takehara K.  Antihistone antibodies in localized scleroderma. J Invest Dermatol, 102: 587, 1994. (abstract)

15.  Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K.  Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res, 287:193-197, 1995.

16.  Ihn H, Shimozuma M, Fujimoto M, Sato S, Kikuchi K, Igarashi A, Soma Y, Tamaki K, Takehara K. Ultrasound measurement of skin thickness in systemic sclerosis. Br J Rheumatol [Rheumatology], 34: 535-538, 1995. 

17.  Ihn H, Kikuchi K, Soma Y, Sato S, Fujimoto M, Tamaki T, Igarashi A, Takehara K.  The stimulatory effects of PDGF and TGF-1 on dermal fibroblast attachment. Acta Derm Venereol, 75:367-371, 1995.

18.  Fujimoto M, Sato S, Ihn H, Kikuchi K, Yamada N, Takehara K. Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol, 22: 563-565, 1995.

19.  Fujimoto M, Sato S, Ihn H, Takehara K.  Autoantibodies to the heat-shock protein hsp73 in localized scleroderma. Arch Dermatol Res, 287: 581-585, 1995. 

20.  Kikuchi K, Kadono T, Fujimoto M, Ihn H, Sato S, Takehara K. Elevated procollagen type I carboxyterminal propeptide production in cultured scleroderma fibroblasts. Dermatology, 190: 104-108, 1995.

21.  Kikuchi K, Kadono T, Ihn H, Sato S, Igarashi A, Nakagawa H, Tamaki K, Takehara K.  Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-1. J Invest Dermatol, 105: 128-132, 1995.

22.  Fujimoto M, Sato S, Ihn H, Kikuchi K, Tamaki K, Takehara K. Autoantibodies to pyruvate dehydrogenase complex in patients with systemic sclerosis. Possible role of anti-E1 alpha antibody as a serologic indicator for development of primary biliary cirrhosis. Arthritis Rheum, 38:985-989, 1995.

23.  Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K.  Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol, 105: 280-284, 1995.

24.  Fujimoto M, Sato S, Takehara K, Nojima Y, Soma Y, Kikuchi K, Ihn H, Igarashi A, Tamaki K.  Detection of antiribosomal P protein antibodies in patients with systemic sclerosis. Br J Rheumatol [Rheumatology], 34: 908-911, 1995. 

25.  Sato S, Fujimoto M, Kikuchi K, Ihn H, Takehara K. Antihistone antibodies in systemic sclerosis. Arthritis Rheum, 38: 1024-1026, 1995.

26.  Fujimoto M, Sato S, Ihn H, Kikuchi K, Takehara K, Tamaki K.  Autoantibodies to pyruvate dehydrogenase complex in systemic sclerosis: Anti-E1 antibodies is a serological indicator for development of primary biliary cirrhosis. J Invest Dermatol, 104: 651 1995. (abstract)

27.  Trojanowska M, Lubinus M, Ohnishi K, Ihn H, LeRoy EC.  TGF- induces phosphorylation of transcription factor Sp1 and modulates binding to the Sp1 responsive element in human collagen 2(I) promoter in vivo. Mol Biol Cell, 6: 254, 1995. (abstract)

28.  Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K.  Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol, 134: 843-847, 1996. 

29.  Ihn H, Sato S, Fujimoto M, Kikuchi K, Igarashi A, Soma Y, Tamaki 

K, Takehara K.  Measurement of anticardiolipin antibodies by ELISA using 2-glycoprotein I (2-GPI) in systemic sclerosis. Clin Exp Immunol, 105: 475-479, 1996.

30.  Ihn H, Ohnishi K, Tamaki T, LeRoy EC, Trojanowska M. Transcriptional regulation of the human 2(I) collagen gene. Combined action of upstream stimulatory and inhibitory cis-acting elements. J Biol Chem, 271: 26717-26723, 1996.

31.  Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K. Elevated soluble CD23 levels in the sera from patients with localized scleroderma. Arch Dermatol Res, 288: 74-78, 1996 .

32.  Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K.  Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol, 106: 729-733, 1996.

33.  Fujimoto M, Sato S, Ihn H, Kikuchi K, Tamaki T, Tamaki K, Takehara K.  Antiubiquitin antibody in localised and systemic scleroderma. Ann Rheum Dis, 55: 399-402, 1996. 

34.  Sato S, Fujimoto M, Kikuchi K, Ihn H, Tamaki K, Takehara K. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res, 288: 358-362, 1996.

35.  Fujimoto M, Sato S, Ihn H, Tamaki T, Kikuchi K, Soma Y, Tamaki K. Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma. Clin Exp Immunol, 105: 297-301, 1996.

36.  Ihn H, LeRoy EC, Trojanowska M.  Oncostatin M stimulates transcription of the human (I) collagen gene via the Sp1/Sp3-binding site. J Biol Chem, 272: 24666-24672, 1997. 

37.  Ihn H, Trojanowska M.  Sp3 is a transcriptional activator of the human 2(I) collagen gene. Nucleic Acids Res, 25: 3712-3717, 1997. 

38.  Ihn H, Sato S, Fujimoto M, Kikuchi K, Kadono T, Tamaki K, Takehara K.  Circulating intercellular adhesion molecule-1 in the sera of patients with systemic sclerosis: enhancement by inflammatory cytokines. Br J Rheumatol [Rheumatology], 36: 1270-1275, 1997. 

39.  Fujimoto M, Shimozuma M, Yazawa N, Kubo M, Ihn H, Sato S, Tamaki T, Kikuchi K, Tamaki K.  Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis. Ann Rheum Dis, 56: 667-670, 1997. 

40.  Fujimoto M, Kikuchi K, Tamaki T, Yazawa N, Kubo M, Ihn H, Sato S, Soma Y, Tamaki K. Distribution of anti-p80-coilin autoantibody in collagen diseases and various skin diseases. Br J Dermatol, 137: 916-920, 1997. 

41.  Trojanowska M, Ihn H, LeRoy EC. Characterization of a novel cis-acting element required for basal activity and oncostatin M stimulation of the human 2(I) collagen gene. Arthritis Rheum, 40: 1020, 1997. (abstract)

42.  Trojanowska M, Ihn H.  Sp3 is a transcriptional activator of the human 2(I) collagen gene. Arthritis Rheum, 40: 1023, 1997. (abstract)

43.  Trojanowska M, Kawakami T, Ihn H, Smith EA, LeRoy EC. Increased expression of TGF- receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. Arthritis Rheum, 40: 1589, 1997 (abstract)

44.  Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K.  Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol [Rheumatology], 37: 1188-1192, 1998. 

45.  Kawakami T, Ihn H, Xu W, Smith E, LeRoy EC, Trojanowska M. Increased expression of TGF- receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF- signaling to scleroderma phenotype. J Invest Dermatol, 110: 47-51, 1998.

46.  Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol, 25: 296-301, 1998. 

47.  Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol, 25: 308-313, 1998.

48.  Yazawa N, Fujimoto M, Kikuchi K, Kubo M, Ihn H, Sato S, Tamaki T, Tamaki K.  High seroprevalence of Helicobacter pylori infection in patients with systemic sclerosis: association with esophageal involvement. J Rheumatol, 25: 650-653, 1998. 

49.  Sato S, Hasegawa M, Nagaoka T, Takamatsu Y, Yazawa N, Ihn H, Kikuchi K, Takehara K.  Autoantibodies against calpastatin in sera from patients with systemic sclerosis. J Rheumatol, 25: 2135-2139, 1998. 

50.  Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K.

Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol, 139: 1049-1051, 1998. 

51.  Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Invest Dermatol, 110: 663, 1998. (abstract)

52.  Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Sato S, Kikuchi K, Tamaki K.  Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol, 117: 383-387, 1999. 

53.  Kubo M, Ihn H, Yazawa N, Sato S, Kikuchi K, Tamaki K.  

Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol, 112: 711-715, 1999 .

54.  Kubo M, Ihn H, Matsukawa A, Kikuchi K, Tamaki K. Dermatomyositis with elevated serum hyaluronate. Clin Exp Dermatol, 24: 275-278, 1999.

55.  Hasegawa M, Sato S, Ihn H, Takehara K.  Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology, 38: 612-617, 1999. 

56.  Yano S, Ihn H, Nakamura K, Okochi H, Tamaki K.  Antinuclear and antithyroid antibodies in 68 Japanese patients with alopecia areata. Dermatology, 199: 191, 1999. 

57.  Ihn H, Tamaki K.  Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Invest Dermatol, 112: 554 1999. (abstract)

58.  Kikuchi K, Kadono T, Kubo M, Ihn H, Tamaki K.  Regulation of vascular endothelial growth factor expression in scleroderma fibroblasts. J Invest Dermatol, 112: 593, 1999. (abstract)  

59.  Kubo M, Ihn H, Yazawa N, Sato S, Kikuchi K, Tamaki K.  Prevalence and specificity of antihistone antibodies in patients with polymyositis/ dermatomyositis. J Invest Dermatol, 112: 601, 1999. (abstract)  

60.  Ihn H, Sato S, Fujimoto M, Igarashi A, Yazawa N, Kubo M, Kikuchi K, Takehara K, Tamaki K.  Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis. Clin Exp Immunol, 119: 203-209, 2000. 

61.  Ihn H, Yazawa N, Kubo M, Yamane K, Sato S, Fujimoto M, Kikuchi 

K, Soma Y, Tamaki K.  Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol, 27: 698-702, 2000.

62.  Ihn H, Tamaki K.  Competition analysis of the human 2(I) collagen promoter using synthetic oligonucleotides. J Invest Dermatol, 114: 1011-1016, 2000. 

63.  Ihn H, Tamaki K.  Oncostatin M stimulates the growth of dermal fibroblasts via a mitogen-activated protein kinase-dependent pathway. J Immunol, 165: 2149-2155, 2000. 

64.  Ihn H, Tamaki K.  Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum, 43: 2240-2247, 2000.

65.  Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K.  Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol, 42: 64-69, 2000.   

66.  Yazawa N, Kikuchi K, Ihn H, Fujimoto M, Kubo M, Tamaki T, Tamaki K.  Serum levels of tissue inhibitor of metalloproteinases 2 (TIMP-2) in patients with systemic sclerosis. J Am Acad Dermatol, 42: 70-75, 2000. 

67.  Sato S, Hasegawa M, Ihn H, Kikuchi K, Takehara K.  Clinical significance of antinuclear matrix antibody in serum from patients with anti-U1RNP antibody. Arch Dermatol Res, 292: 55-59, 2000. 

68.  Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K.  Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol, 27: 930-934, 2000. 

69.  Kubo M, Ihn H, Yamane K, Kikuchi K, Yazawa N, Soma Y, Tamaki K.  Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology, 39: 632-636, 2000. 

70.  Nagaoka T, Sato S, Hasegawa M, Ihn H, Takehara K.  Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol, 27: 1917-1921, 2000. 

71.  Kubo M, Ihn H, Yamane K, Yazawa N, Kikuchi K, Soma Y, Tamaki K.  Increased serum levels of soluble vascular cell adhesion molecule-1 and soluble E-selectin in patients with polymyositis/ dermatomyositis. Br J Dermatol, 143: 392-398. 2000. 

72.  Yamane K, Ihn H, Asano Y, Yazawa N, Kubo M, Kikuchi K, Soma Y, Tamaki K.  Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology, 39: 1269-1271, 2000.  

73.  Yasuoka H, Kuwana M, Ihn H, Yamane K, Mimori T, Ikeda Y, Kawakami Y.  Novel autoantibody to testicular antigen in patienst with systemic sclerosis (SSc). Arthritis Rheum, 43: S263, 2000. (abstract)

74.  Ihn H, Yamane K, Kubo M, Tamaki K.  Blockade of endogenous transforming growth factor  signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor receptors. Arthritis Rheum, 44: 474-480, 2001. 

75.  Ihn H, Ihn Y, Trojanowska M.  Spl phosphorylation induced by serum stimulates the human 2(I) collagen gene expression. J Invest Dermatol, 117: 301-308, 2001.   

76.  Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor  receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum, 44: 731-734, 2001.   

77.  Yazawa N, Ihn H, Yamane K, Etoh T, Tamaki K.  The successful treatment of prurigo pigmentosa with macrolide antibiotics. Dermatology, 202: 67-69, 2001. 

78.  Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Tamaki K.  Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. Arthritis Rheum, 44: 1363-1369, 2001   

79.  Takeda N, Ihn H, Teramoto S.  Markedly increased levels of IL-6 and CA125 in pleural fluid of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing, 30: 171, 2001.  

80.  Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N, Tamaki K.  Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatology, 40: 683-686, 2001.   

81.  Yazawa N, Ihn H, Yamane K, Kubo M, Fujimoto M, Kikuchi K, Soma Y, Tamaki K.  Elevated circulating soluble CD30 levels in patients with polymyositis/dermatomyositis. Br J Dermatol, 145: 676-678, 2001. 

82.  Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N Tamaki K.  Anti-U1RNP antibodies in patients with localized scleroderma. Arch Dermatol Res, 293: 455-459, 2001. 

83.  Yamane K, Ihn H, Kubo M, Kuwana M, Asano Y, Yazawa N Tamaki K.  Anti-U3 snRNP antibodies in localised scleroderma. Ann Rheum Dis, 60: 1157-1158, 2001.

84.  Kubo M, Ihn H, Kuwana M, Yamane K, Yazawa N, Tamaki K. Prevalence in myositis of antibodies recognizing anti-U3 RNA probably in a novel complex with 22/25 kD protein and not fibrillarin. Clin Exp Immunol, 126: 339-344, 2001.  

85.  Kubo M, Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K.  Differential expression of TGF- receptors in squamous cell carcinoma. Br J Dermatol, 145: 840-842, 2001.

86.  Yamane K, Ihn H, Kubo M, Tamaki K.  Epidermal growth factor up-regulates transforming growth factor- receptor type II in human dermal fibroblasts via p38 mitogen-activated protein kinase pathway. J Invest Dermatol, 117: 469, 2001. (abstract)

87.  Asano Y, Ihn H, Yamane K, Kubo M, Yazawa N, Fujimoto M, Tamaki K.  The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol, 117: 551, 2001. (abstract)

88.  Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K.  Interleukin-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase-dependent pathway. J Immunol, 168: 1895-1902, 2002.

89.  Ihn H, Tamaki K.  Mitogenic activity of dermatofibrosarcoma protuberans is mediated via an extracellular signal related kinase dependent pathway. J Invest Dermatol, 119: 954-960, 2002.

90.  Ihn H.  Pathogenesis of fibrosis: role of TGF- and CTGF. Curr Opin Rheumatol, 14: 681-685, 2002.

91.  Ihn H.  The role of TGF- signaling in the pathogenesis of fibrosis in scleroderma.  Arch Immunol Ther Exp, 50: 325-331, 2002.

92.  Ihn H, Asano Y, Kubo M, Yamane K, Jinnin M, Yazawa N, Fujimoto M, Tamaki K.  Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/ dermatomyositis: Correlation with interstitial lung disease. Rheumatology, 41: 1268-1272, 2002.

93.  Soma Y, Mizoguchi M, Yamane K, Yazawa N, Kubo M, Ihn H, Kikuchi K, Tamaki K.  Specific inhibition of human skin fibroblast chemotaxis to platelet-derived growth factor A-chain homodimer by transforming growth factor-1. Arch Dermatol Res, 293: 609-613, 2002.

94.  Kubo M, Ihn H, Kuwana M, Asano Y, Tamaki T, Yamane K, Tamaki K.  Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap. Rheumatology, 41: 531-534, 2002.

95.  Kubo M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.  Prevalence of 52-kDa and 60- kDa Ro/SS-A autoantibodies in Japanese patients with polymyositis/ dermatomyositis. J Am Acad Dermatol, 47: 148-151, 2002.  

96.  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.  A case of linear scleroderma with muscle calcification. Br J Dermatol, 146: 1084-1086, 2002.

97.  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K.  Serum levels of tissue inhibitor of metalloproteinases in patients with mixed connective tissue disease. Clin Exp Rheumatol, 20: 539-542, 2002.

98.  Yamane K, Ihn H, Kubo M, Tamaki K.  Increased transcriptional activities of transforming growth factor- receptors in scleroderma fibroblasts. Arthritis Rheum, 46: 2421-2428, 2002.

99.  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.  Autoimmune 

response to 52-kDa and 60- kDa Ro/SS-A antigens in mixed connective tissue disease. Br J Dermatol, 147: 827-829, 2002.

100.  Kubo M, Ihn H, Yamane K, Tamaki K.  Up-regulated expression of transforming growth factor  receptors in dermal fibroblasts of the skin sections from patients with systemic sclerosis. J Rheumatol, 29: 2558-2564, 2002.

101.  Ihn H, Yamane K, Tamaki K.  Interleukin-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 MAP kinase-dependent pathway. J Invest Dermatol, 119: 285, 2002. (abstract) 

102.  Yamane K, Ihn H, Tamaki K.  Epidermal growth factor up-regulates transforming growth factor-receptor type II in human dermal fibroblasts via phosphoinositide 3 kinase Akt gnaling pathway. J Invest Dermatol, 119: 274, 2002. (abstract)

103.  Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K.  Increased expression of integrin V5 in scleroderma fibroblasts. J Invest Dermatol, 119: 225, 2002. (abstract) 

104.  Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K.  Circulating soluble CD40 ligand in patients with eosinophilic faciitis. Ann Rheum Dis, 62: 190-191, 2003.

105.  Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K.  The prevalence and clinical significance of anti-U1RNA antibodies in patients with systemic sclerosis. J Invest Dermatol, 120: 204-210, 2003.

106.  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K.  Plasma plasmin-2 plasmin inhibitor complex levels are increased in systemic sclerosis with pulmonary hypertension. Rheumatology, 42: 240-243, 2003.

107.  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K.  Clinical features of patients with systemic sclerosis accompanied by rheumatoid arthritis. Clin Exp Rheumatol, 21: 91-94, 2003.

108.  Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K.  Elevated circulating soluble CD40 ligand in patients with mixed connective tissue disease. Clin Rheumatol, 22: 37-39, 2003

109.  Tsunemi Y, Ihn H, Shimada Y, Takehara K, Manabe M, Tamaki K.  Rosai-Dorfan disease presenting as large pigmented indurated plaques. Acta Derm Venereol, 83: 57-58, 2003.

110.  Tsunemi Y, Ihn H, Idezuki T, Okochi H, Tamaki K. Guttate psoriasis in association with hepatocellular carcinoma. Acta Derm Venereol, 83: 70-71, 2003.

111.  Tsunemi T, Ihn H, Nakamura K, Tamaki K.  Post-transplantation chronic graft-versus-host disease with overlapping features similar to those of various collagen diseases. Int J Dermatol, 42: 292-294, 2003.

112.  Yamane K, Ihn H, Tamaki K.  Epidermal growth factor up-regulates expression of transforming growth factor- receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/ Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum, 48: 1652-1666, 2003.

113.  Jinnin M Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.  Effect of D-penicillamine on pulmonary fibrosis in patients with systemic sclerosis. Ann Rheum Dis, 62: 1019-1020, 2003.

114.  Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K.  Antagonistic effects of TNF- on TGF- signaling through downergulation of TGF receptor type II in human dermal fibroblasts. J Immunol, 171: 3855-3862, 2003.

115.  Tsunemi Y, Ihn H, Hattori N, Saeki H, Tamaki K.  Multiple eruptive dermatofibromas with CD34+ cells in a patient with hyperglyceridemia. Dermatology, 207: 319-321, 2003.

116.  Tsunemi Y, Ihn H, Saeki H, Tamaki K.  Cholinergic urticaria successfully treated with scopolamine butylbromide. Int J Dermatol, 42: 850, 2003.

117.  Tsunemi Y, Ihn H, Saeki H, Tamaki K.  Epithelioid granulomas in post-transplantation chronic graft-versus-host disease. Br J Dermatol, 149: 898-899, 2003.   

118.  Yasuoka H, Ihn H, Medsger TA Jr., Hirakata M, Kawakami Y, Ikeda Y, Kuwana M.  A novel peotein highly expressed in testis is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies. J Immunol, 171: 6883-6890, 2003.

119.  Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K.  Elevated serum levels of manganese superoxide dismutase in patients with eosinophilic fasciitis. Clin Rheumatol, 22: 505, 2003.

120.  Ihn H, Yamane K, Tamaki K.  Mitogen-activated protein kinase p38 is involved in transforming growth factor--induced transcriptional activation of the human 2(I) collagen gene. FASEB J, 17: A1017, 2003. (abstract)

121.  Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K.  Upregulated tenascin-C expression in stroma around basal cell carcinoma: Induction by interleukin-13 in human dermal fibroblasts via phosphoinositide 3-kinase/ Akt and protein C kinase signaling pathway. FASEB J, 17: A1013, 2003. (abstract)

122.  Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K.  Antagonistic effects of TNF on TGF  signaling through downregulation of TGF receptor type II in human dermal fibroblasts. FASEB J, 17: A1017- A1018, 2003. (abstract)

123.  Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K.  Increased expression of integrin V5 in scleroderma fibroblasts. FASEB J, 17: A1351, 2003. (abstract)

124.  Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K.  Constitutive complex formation of Smad7 with transforming growth factor (TGF)- receptors in scleroderma fibroblasts. Arthritis Rheum 48: S155, 2003. (abstract)

125. Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K.  Tenascin-C upregulatation by transforming growth factor- in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Arthritis Rheum 48: S416, 2003. (abstract)

126.  Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K.  Impaired Smad7-Smurf-mediated negative regulation of TGF- signaling in scleroderma fibroblasts. J Clin Invest, 113: 253-264, 2004.

127.  Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K.  Tenascin-C upregulation by transforming growth factor- in human dermal fibroblasts involves Smad3, Sp1 and Ets-1.Oncogene, 23: 1656-1667, 2004.

128.  Tsunemi Y, Ihn H, Saeki H, Tamaki K.  A case of lichen sclerosus et atrophicus with marked fibrosis in the dermis: analysis of fibrogenenetic cytokines by reverse transcriptase- polymerase chain reaction. J Dermatol, 31: 142-145, 2004.

129.   Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K.  Increased expression levels of integrin v5 on scleroderma fibroblasts. Am J Pathol, 164: 1275-1292, 2004.

130.  Tsunemi Y Saeki H, Ihn H, Tamaki K.  Eosinophilic pustular folliculitis with a butterfly rash-like distribution. Dermatology, 208: 229-230, 2004.

131.  Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K.  Phosphatidylinositol 3-kinase is involved in 2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol, 172: 7123-7135, 2004.

132.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Epidermal growth factor induces fibronectin expression in human dermal fibroblasts via protein kinase C  signaling pathway. J Invest Dermatol, 122: 1390-1398, 2004.

133.  Jinnin M, Ihn H, Yazawa N, Asano Y, Yamane K, Tamaki K.  Serum levels of manganese superoxidase dismutase in patients withl localized scleroderma. Exp Dermatol, 13: 357-360, 2004.

134.  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K. Serum matrix metaloproteinase-3 in systemic sclerosis. Arch Dermatol Res, 296: 25-29, 2004.

135.  Asano Y, Ihn H, Shikada J, Kadono T, Kikuchi K, Tamaki K.  A case of peplomycin-induced scleroderma. Br J Dermatol,150: 1213-1214, 2004.

136.  Sato-Takeda M, Ihn H, Ohashi J, Tsuchiya N, Satake M, Arita H, Tamaki K, Hanaoka K, Tokunaga K, Yabe T.  The human histocompatibility leukocyte antigen (HLA) haplotype is associated with the onset of postherpetic neuralgia after herpes zoster. Pain, 110: 329-336, 2004.

137.  Tsunemi Y, Ihn H, Kakinuma T, Tamaki K.  Lesional skin of linear IgA bullous dermatosis expresses growth-regulated peptide (GRO)-. J Dermatol, 31: 546-551, 2004. 

138.  Jinnin M, Ihn H, Yamane K, Asano Y, Yazawa N, Tamaki K.  Serum levels of tissue inhibitor of metalloproteinase-1 and 2 in patients with eosinophilic faciitis. Br J Dermatol, 151: 407-412, 2004.

139.  Tsunemi Y, Tada Y, Saeki H, Ihn H, Tamaki K.  Multiple dermatofibromas in a patients with systemic lupus erythematosus and Sjogren’s syndrome. Clin Exp Dermatol, 29: 483-485, 2004.

140.  Jinnin M, Ihn H, Yamane K, Tamaki K.  Interleukin-13 stimulates the transcription of the human 2(I) collagen gene in human dermal fibroblasts. J Biol Chem, 279: 41783-41791, 2004.

141.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K.  Rheumatoid factor isotypes and anti-agalactoyl IgG antibodies in systemic sclerosis. Br J Dermatol, 151: 803-808, 2004.

142.  Ihn H.  Pathogenesis of scleroderma: The role of autocrine TGF- signaling. Connective Tissue 36: 209-216, 2004.

143.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Fibronectin expression is post-transcriptionally up-regulated by epidermal growth factor in human dermal fibroblasts via protein kinase C- signaling pathway. J Invest Dermatol, 122: A30, 2004. (abstract)

144.  Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K.  Constitutive phosphorylated Smad3 interacts with Sp1 and p300/CBP in scleroderma fibroblasts. J Invest Dermatol, 122: A93, 2004. (abstract)

145.  Jinnin M, Ihn H, Asano Y, Yamane K, Tamaki K.  Tenascin-C up-regulation by transforming growth factor-b in human dermal fibroblasts involves Smad3, Sp1, and Ets1. J Invest Dermatol, 122: A94, 2004. (abstract)

146.  Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K.  Regulation of fibrogenic/fibrolytic genes by platelet derived growth factor C, a novel growth factor, in human dermal fibroblasts. J Cell Physiol, 202: 510-517, 2005.

147.  Yamane K, Suzuki H, Ihn H, Kato M, Yoshikawa H, Tamaki K.  Cell type-specific regulation of the TGF-responsive 2(I) collagen gene by CpG methylation. J Cell Physiol, 202: 822-830, 2005.

148.  Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K.  Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol, 124: 324-330, 2005.

149.  Jinnin M, Ihn H, Yamane K, Mimura Y, Asano Y, Tamaki K.  2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res, 33: 1337-1351, 2005.

150.  Ihn H.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep, 7: 156-162, 2005.

151.  Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K.  Differential effects of the immunosuppressant FK506 on human 2(I) collagen gene expression and transforming growth factor  signaling in normal and scleroderma fibroblasts. Arthritis Rheum, 52: 1237-1247, 2005.

152.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N Tamaki K.  Clinical and laboratory features of scleroderma patients developing skeletal myopathy. Clin Rheumatol, 24: 99-102, 2005.  

153.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K.  Serum levels of anti-agalactosyl IgG antibodies in mixed connective tissue disease. Br J Dermatol, 152: 806-808, 2005.

154.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-signaling in cultured scleroderma fibroblasts. Am J Pathol, 166: 1451-1463, 2005.

155.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol, 124: 886-892, 2005.

156.  Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M, Yamane K, Tamaki K.  A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology, 44: 824-826, 2005.

157.  Nakashima H, Yamane K, Ihn H, Nakamura K, Watanabe R Kuwano Y, Takekoshi T, Watanabe T, Hattori N, Fujimoto M, Tamaki K. Drug-induced hypersensitivity syndrome associated with transient hypogammaglobulinemia and increase in serum IgE level. Dermatology, 210: 349-352, 2005.

158.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol, 30: 405-408, 2005.

159.  Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K.  Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res, 33: 3540-3549, 2005.

160.  Ihn H, Yamane K, Tamaki K.  Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J Invest Dermatol, 125: 247-255, 2005.

161.  Tsunemi Y, Shimazu K, Saeki H, Ihn H, Tamaki K.  Eccrine angiomatous hamartoma with massive mucin deposition. Eur J Dermatol, 15: 291-292, 2005.

162.  Jinnin M, Ihn H, Yazawa N, Tamaki K.  Serum levels of manganese superoxidase dismutase in patients with mixed connective tissue disease. Clin Exp Rheumatol,23: 549-550, 2005.

163.  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.  Sclerosing paniculitis is associated with pulmonary hypertension in systemic sclerosis. Br J Dermatol, 153: 579-583, 2005.

164.  Tsunemi Y, Saeki H, Ihn H, Tamaki K.  Recurrent cutaneous eosinophilic vasculitis presenting as urticarial plaques. Acta Derm Venereol, 85: 380-381, 2005.

165. Tsunemi Y, Ihn H, Fujita H, Asashima N, Saeki H, Tamaki K. Square-shaped scleredema in the back: probably induced by mechanical stress. Int J Dermatol, 44: 769-770, 2005.

166.  Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of V5 intgrin-mediated activation of latent transforming growth factor 1 in autocrine transforming growth factor signaling in systemic sclerosis fibroblasts. Arthritis Rheum, 52: 2897-2905, 2005.

167.  Tsunemi Y, Ihn H, Saeki H, Tamaki K.  Generalized eruptive syringoma. Pediatr Dermatol, 22: 492-493, 2005.

168.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Yazawa N, Tamaki K.  Anti-agalactoyl immunoglobulin G antibodies in localized scleroderma. Int J Dermatol, 44: 817-820, 2005.

169.  Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K.  Increased expression of integrinv3 contributes to the establishment of autocrine TGF- signaling in scleroderma dermal fibroblasts. J Immunol, 175: 7708-7718, 2005.

170.  Maekawa T, Jinnin M, Ihn H, Tamaki K. The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans. J Invest Dermatol, 124: A89 (532), 2005. 

171.  Jinnin M, Ihn H, Yamane K, Mimura Y, Asano Y, Tamaki K.  2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. J Invest Dermatol, 124: A89 (534), 2005. 

172.  Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K.  Platelet derived growth factor induced tenascin-C transcription is phosphoinositide 3-kinase/ Akt –dependent and mediated by Ets family transcription factors. J Cell Physiol, 206: 718-727, 2006.

173.  Ihn H, Yamane K, Asano Y, Jinnin M, Tamaki K.  Constitutive phosphorylated Smad3 interactes with Sp1 and p300/CBP in scleroderma fibroblasts. Rheumatology, 45: 157-165, 2006.

174.  Jinnin M, Ihn H, Tamaki K.  Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-1-induced extracellular matrix expression. Mol Pharmacol, 69: 597-607, 2006.

175.  Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. Increased expression of intgrin v5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol, 168: 499-510, 2006.

176.  Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K.  Upregulation of tenascin-C expression by IL-13 in human dermal fibroblasts via the phosphoinositide 3-kinase/ Akt and protein kinase C signaling pathways. J Invest Dermatol, 126: 551-560, 2006.

177.  Asano Y, Ihn H, Kubo M, Jinnin M, Mimura Y, Ashida R, Tamaki K.  Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis. Rheumatology, 45: 303-307, 2006.

178.  Kubo M, Ihn H, Yamane K, Tamaki K.  The expression levels and the differential expression of transforming growth factor-receptors in dermatofibroma and dermatofibrosarcoma protuberans. Br J Dermatol, 154: 919-925, 2006.

179.  Asano Y, Ihn H, Maekawa T, Kadono T, Tamaki K.  High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: Report on one case and review of the literature. Clin Rheum, 25: 396-398, 2006.

180.  Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K.  Potential regulatory elements of the constitutively up-regulated 2(I) collagen gene in scleroderma dermal fibroblasts. Biochem Biophys Res Commun, 343: 904-909, 2006.       

181.  Kuwano Y, Ihn H, Yazawa N, Kakinuma T, Asahina A, Kikuchi K, Tamaki K.  Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin. Acta Derm Venereol, 86: 158-159, 2006.

182.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Epidermal growth factor affects the synthesis and degradation of type I collagen in cultured human dermal fibroblasts. Matrix Biology, 25: 202-212, 2006.

183.  Asano Y, Ihn H, Jinnin M, Mimura Y, Tamaki K.  Involvement of v5 intgrin in the establishment of autocrine TGF- signaling in dermal fibroblasts derived from localized scleroderma. J Invest Dermatol, 126: 1761-1769, 2006.

184.  Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K.  Rheumatoid factor isotypes in mixed connective tissue disease. Clin Rheum, 25: 572-574, 2006.

185.  Muchemwa FC, Nakatsura T, Ihn H, Kageshita T.  Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell. Br J Dermatol, 155: 582-585, 2006.

186.  Nakashima H, Komine M, Sasaki K, Mitsui H, Fujimoto M, Ihn H, Asahina A, Kikuchi K, Tamaki K.  Necrolytic migratory erythema without glucagonoma in a patient with short bowel syndrome.  J Dermatol, 33: 557-562, 2006. 

187.  Asano Y, Ihn H, Kubo M, Jinnin M, Mimura Y, Ashida R, Tamaki K.  Clinical significance of serum matrix metalloproteinase-13 levels in patients with localized scleroderma. Clin Exp Rheumatol, 24: 394-399, 2006.

188. Kuwano Y, Asahina A, Watanabe R, Fujimoto M, Ihn H, Tamaki K.  Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia. Int J Dermatol 45: 1249-1251, 2006 

189.  Masui Y, Sugaya M, Kagami S, Fujita H, Yano S, Nagao M, Komine M, Saeki H, Ihn H, Kikuchi K, Tamaki K.  Sezary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/CCL27. Clin Exp Dermatol, 32: 57-59, 2007.

190.  Yamane K, Asano Y, Tamaki K, Ihn H.  Epidermal growth factor up-regulates transforming growth factor - receptor II in human dermal fibroblasts via the p38 mitogen-activated protein kinase pathway. Biochem Biophys Res Commun, 352: 69-77, 2007.

191.  Saeki H, Hosono S, Tsunemi Y, Sasaki K, Kadono T, Ihn H, Komine M, Asahina A, Kikuchi K, Tamaki K.  Psoriasis vulgaris associated with superior vena cava syndrome due to lung cancer metastasis. J Dermatol, 34: 356-359, 2007. 

192.  Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K, Tamaki K.  High-dose intravenous immune globulin infusion as treatment for diffuse scleroderma. Br J Dermatol, 156: 1058-1060, 2007.

193.  Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K.  Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor- signaling in scleroderma fibroblasts. Arthritis Rheum, 56: 1694-1705, 2007.

194.  Mimura Y, Yazawa N, Tada Y, Ihn H, Tamaki K.  Anti-p53 antibodies in patients with systemic sclerosis. Int J Dermatol 46: 549-550, 2007.

195.  Ashida R, b, Mimura Y, Jinnin M, Asano Y, Kubo M, Tamaki K.  Clinical features of scleroderma patients with contracture of phalanges. Clin Rheum, 26: 1275-1277, 2007.

196.  Mimura Y, Yazawa N, Tamaki Z, Ashida R, Jinnin M, Asano Y, Tada Y, Kubo M, Ihn H, Tamaki K.  Anti-p53 antibodies in patients with dermatomyositis/polymyositis. Clin Rheum, 26: 1328-1331, 2007.  

197.  Ihn H.  p38 MAP kinase inhibitors in dermatology. Exp Rev Dermatol, 2: 403-407, 2007.

198.  Asano Y, Ihn H, Tamaki K.  Linear connective tissue nevus. Pediatr Dermatol, 24: 439-441, 2007

199.  Asano Y, Ihn H, Tamaki K.  An usual manifestation of linear scleroderma ‘en coup de sabre’ on the vertex and frontparietal regions. Clin Exp Dermatol, 32: 758-759, 2007.

200.  Inoue Y, Miyasaka J, Ono T, Ihn H.  The growth of Vibrio vulnificus and the habitat of infected patients in Kumamoto. Bioscience Trends, 1: 134-139, 2007.

201.  Zhang XY, Makino T, Muchemwa FC, Lin T, Wakasugi S, Egawa K, Ihn H.  Activation of the extracellular signal-regulated kinases signaling pathway in squamous cell carcinoma of the skin. Bioscience Trends, 1: 156-160, 2007.

202.  Xie Y, Zhang X, Inoue Y, Wakasugi S, Makino T, Ihn H.  Expression of CD1a and CD86 on scleroderma Langerhans cells. Eur J Dermatol, 18: 50-54, 2008.

203.  Ihn H.  Autocrine TGF- signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci, 49: 103-113, 2008.

204.  Makino K, Umeda K, Uezu A, Hiragami Y, Sakamoto T, Ihn H, Nakanishi H. Identification and characterization of the novel centrosomal protein centlein. Biochem Biophys Res Commun, 366: 958-962, 2008.

205.  Muchemwa FC, Ma D, Inoue Y, Curtin JA, Bastian BC, Ihn H, Kageshita T.  Constitutive activation of the phosphatidyl ionositol 3 kinase signaling pathway in acral lentiginous melanoma. Br J Dermatol, 158: 411-413, 2008.

206.  Hashimoto S, Egawa K, Ihn H, Igarashi A, Matsunaga T, Tateishi S, Yamaizumi M.  A new disorder in UV-induced skin cancer with defective DNA repair distinct from xeroderma pigmentosum or Cocyayne syndrome. J Invest Dermatol, 128: 694-701, 2008.

207.  Inoue Y, Ono T, Matsui T, Miyasaka J, Kinoshita Y, Ihn H.  Epidemiological survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol, 35: 12-139, 2008.

208.  Xie Y, Zhang X, Wakasugi S, Makino T, Inoue Y, Ihn H.  Immunohistochemical characterization of the cellular infiltrate in localized scleroderma. Int J Dermatol, 47: 438-442, 2008.

209.  Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H.  Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol, 35: 206-214, 2008.

210.  Ishihara T, Igata T, Masuguchi S, Matsushita S, Sakai K, Ihn H. Submental perforator flap: location and number of submental perforating vessels. Scan J Plast Reconstr Surg Hand Surg 42: 127-131, 2008

211.  Muchemwa FC, Nakatsura T, Fukushima S, Nishimura Y, Kageshita T, Ihn H.  Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Res, 18: 166-171, 2008.

212.  Ikeda I, Nishimoto K, Sasamoto K, Nagira K, Ono T, Ihn H.  Alkaline trypan blue as a stain for superficial fungi. Br J Dermatol, 158: 1371-1401, 2008.

213.  Hashimoto S, Suga T, Kudo E, Ihn H, Uchino M, Tateishi S.  Adult-onset neurological degeneration in a patient with Cockayne syndrome and a null mutation in the CSB gene. J Invest Dermatol, 128: 1597-1599, 2008.

214.  Fukushima S, Kidou M, Ihn H.  Fixed drug eruption caused by cashew nut. Allergol Int, 57: 285-287, 2008.

215.  Fukushima S, Egawa K, Nishi H, Wakasugi S, Ishii N, Hashimoto T, Yancey KB, Ihn H.  Two cases of anti-epiligrin cicatricial pemphigoid with and without associated malignancies. Acta Dermato Venereol, 88: 484-487, 2008. 

216.  Saeki H, Watanabe A, Tada Y, Kakinuma T, Komine M, Ihn H, Asahina A, Etoh T, Kitanaka S, Sato U, Kano H, Igarashi T, Tamaki K.  Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J Dermatol, 35: 601-603, 2008.

217.  Masui Y, Komine M, Kadono T, Ishiura N, Maekawa T, Ihn H, Kikuchi K, Tamaki K.  Proliferating trichilemmal cystic carcinoma: a case containing differentiated and dedifferentiated parts. J Cutan Pathol, 35: 55-58, 2008. 

218. Ishihara T, Masuguchi S, Ihn H.  Using the Smallest Skin Excision without Dog-Ear Formations: Utilizing Histopathology on the Face. Dermatol Surg, 34: 1404-1406, 2008.

219.  Sakai K, Wakasugi S, Muchemwa FC, Ihn H.  Quick detection of herpes viruses from skin vesicles and exudates without nucleic acid extraction using the multiplex PCR method. Bioscience Trends, 2: 164-168, 2008.

220.  Hashimoto S, Egawa K, Ihn H, Tateishi S.  Non-radioisotope method for diagnosing photosensitive disorders and a new marker for xeroderma pigmentosum variant. J Dermatol, 36: 130-135, 2009. 

221.  Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z, Takigawa M, Seishima M, Tanaka T, Miyachi Y, Katayama I, Horiguchi Y, Miyagawa S, Furukawa F, Twatsuki K, Hide M, Tokura Y, Furue M, Hashimoto T, Ihn H, Fujiwara S, Nishikawa T, Ogawa H, Kitajima Y, Hashimoto K.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 60: 595-603, 2009.

222.  Kogushi-Nishi H, Kawasaki J, Kageshita T, Ishihara T, Ihn H.  The prevalence of melanocytic nevi on the soles in the Japanese population. J Am Acad Dermatol, 60: 767-771, 2009.

223.  Fukushima S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Haruta M, Ikuta Y, Ikeda T, Kageshita T, Ihn H, Nishimura Y, Senju S.  Multiple antigen-targeted immunotherapy with -galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunotherapy, 32: 219-231, 2009. 

224.  Jinnin M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K.  Retrospective study of clinical and laboratory features in Japanese scleroderma patients with cardiac involvement. J Dermatol Sci, 55: 70-72, 2009. 

225.  Zhang X, Egawa K, Xie Y, Ihn H.  The expression of SnoN in normal human skin and cutaneous keratinous neoplasms. Int J Dermatol, 48: 579-583, 2009.

226.  Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H.  Alternatively activated macrophages (M2 macrophages) in the skin of patients with localized scleroderma. Exp Dermatol, 18: 727-729, 2009.

227.  Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, Tamaki K.  Clinical and laboratoryu features of scleroderma patients with telangiectasia. Clin Exp Dermatol, 34: 781-783, 2009.

228.  Nakashima H, Sugaya M, Minatani T, Ohmatsu H, Asano N, Fujimoto M, Kikuchi K, Ihn H, Tamaki K.  Cutaneous / T-cell lymphoma treated with retinoid and narrowband ultraviolet B. Clin Exp Dermatol, 34: e345-346, 2009.

229. Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M.  Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. Rheumatology 48: 1570-1574, 2009.

230.  Makino T, Johno T, Fukushima S, Wakasugi S, Inoue Y, Ihn H.  Decreased serum IL-7 levels in patients with systemic sclerosis. Clin Exp Rheumatol 54s: 68-69, 2009.

231.  Miyashita A, Jono T, Makino T, Yoshino Y, Ihn H.  Lupus erythematosus profundus: clinical and pathological features of 12 cases. Arch Dermatol Res 301: 51, 2009 (abstract).

232.  Ohshima Y, Yajima I, Yanagishita T, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, Inoue Y, Ihn H, Matsumoto Y, Kato M.  CD109 expression levels in human malignant melanoma. J Dermatol Sci, 57: 132-146, 2010.

233.  Matsuda M, Hoshino T, Yamashita Y, Tanaka KI, Maji D, Sato K, Adachi H, Sobue G, Ihn H, Funasaka Y, Mizushima T.  Prevention of ultraviolet B radiation-induced epidermal damage by expression of heat shock protein 70. J Biol Chem, 285: 5848-5858, 2010.

234.  Nishi H, Inoue Y, Kageshita T, Takata M, Ihn H.  The expression of human high molecular weight melanoma-associated antigen in acral lentiginous melanoma. Bioscience Trends, 4: 86-89. 2010.

235.  Akiyama M, Sakai K, Yanagi T, Fukushima S, Ihn H, Hitomi K, Shimizu H.  Transglutaminase 1 preferred substrate prptide K5 is an efficient tool in diagnosis of lamellar ichthyosis. Am J Pathol, 176: 1592-1599, 2010.  

236.  Igata T, Jinnin M, Makino T, Moriya C, Muchemwa F, Ishihara T, Ihn H.  Up-regulated type I collagen expression by the inhibition of Rac1 signaling pathway in human dermal fibroblasts. Biochem Biophys Res Commun, 393: 101-105, 2010.

237.  Hoshino T, Matsuda M, Yamashita Y, Takehara M, Fukuya M, Mineda K, Maji D, Ihn H, Adachi H, Sobue G, Funasaka Y, Mizushima T.  Supression of melanin production by expression of HSP70. J Biol Chem, 285: 13254-13263, 2010.

238.  Makino T, Jinnin M, Muchemwa F, Fukushima S, Ihn H.  Basic fibroblast growth factor stimulates the proliferation of human dermal fibroblasts via the ERK1/2 and JNK pathways. Br J Dermatol, 162: 717-723, 2010.

239.  Jinnin M, Makino T, Kajihara I, Honda N, Makino K, Ogata A, Ihn H.  Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis. Br J Dermatol, 162: 751-758, 2010.

240.  Muchemwa FC, Jinnin M, Wakasugi S, Sakamoto M, Inoue Y, Ishihara T, Ihn H.  A novel COL1A1 exon 14/PDGFB fusion gene in dermatofibrosarcoma protuberans, Eur J Dermatol, 20: 390-391, 2010.

241.  Muchemwa FC, Wakasugi S, Honda Y, Ihn H.  PDGFB quantification is a useful tool in the diagnosis of dermatofibrosarcoma protuberans: a study of 10 cases. Clin Exp Dermatol, 35: 295-299, 2010.

242.  Torii H, Nakagawa H, Iizuka H, Aoyagi S, Okuyama R, Ohtsuki M, Abe M, Takamori K, Matsuba S, Terui T, Igarashi A, Kawashima M, Amagai M, Takae Y, Eto H, Ikeda S, Komine M, Saeki H, Hayakawa K, Kitami A, Watanabe H, Takehara K, Shimada S, Kitajima Y, Takigawa M, Morita A, Yamanaka K, Takahashi K, Tarutani M, Tani M, Kubota Y, Nakayama J, Ihn H.  Inflixmab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci, 59: 40-49, 2010.

243.  Kato T, Inoue Y, Ishihara T, Kageshita T, Ihn H.  Amelanotic malignant melanoma where primary lesion was discovered 5 years after metastasis in the lymph node. J Dermatol, 37: 730-734, 2010.

244.  Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, Yonemura Y, Komohara Y, Takeya M, Mitsuya H, Ihn H.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arhritis Res Ther, 12: R128 (1-10), 2010.

245.  Kawashima T, Tada Y, Asano Y, Yazawa N, Tomita M, Tamaki Z, Kubo M, Ihn H, Sugaya M, Kadono T, Tamaki K, Sato S.  Serum TARC/CCL17 levels are increased in dermatomyositis associated with interstitial lung disease. J Dermatol Sci, 60: 52-54, 2010.

246.  Honda N, Jinnin M, Kajihara I, Makino T, Fukushima T, Ihn H.  Impaired lymphangiogenesis due to excess VEGF-D/Flt-4 signaling in the skin of patients with systemic sclerosis. Br J Dermatol, 163: 776-780, 2010.

247.  Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, Ihn H.  Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One, 5: e14334, 2010.

248.  Kawashita Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, Masuguchi S, Fukushima S, Inoue Y, Ihn H.  Circulating miR-29a levels in patients with scleroderma spectrum disorder. J Dermatol Sci, 61: 67-69, 2011.

249.  Asano Y, Ihn H, Jinnin M, Tamaki K.  Altered dynamics of TGF- receptors in scleroderma fibroblasts. Ann Rheum Dis, 70: 384-387, 2011.

250.  Moriya C, Jinnin M, Yamane K, Maruo K, Muchemwa FC, Igata T, Makino T, Fukushima S, Ihn H.  Expression of matrix metalloproteinase-13 is controlled by IL-13 via PI3K/Akt3 and PKC- in normal dermal fibroblasts. J Invest Dermatol, 131:  655-661, 2011.

251.  Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, Masuguchi S, Ishihara T, Inoue Y, Jinnin M, Ihn H.  Circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci, 61: 187-193, 2011.

252.  Oyama R, Jinnin M, Kakimoto A, Kanemura H, Ichihara A, Fujisawa A, Honda N, Masuguchi S, Fukushima S, Maruo K, Ihn H.  Circulating microRNA associated with TNF signaling pathway in patients with plaque psoriasis. J Dermatol Sci, 61: 209-211, 2011.

253.  Makino K, Fukushima S, Maruo K, Egawa K, Nishimoto K, Ihn H.  Cutaneous hyalohyphomycosis by Scedosporium apiospermum in an immunocompromised patient. Mycoses, 54: 259-261, 2011.

254.  Xie Y, Jinnin M, Zhang X, Wakasugi S, Makino T, Inoue Y, Masuguchi S, Sakai K, Jinnin M, Ihn H.  Immunohistochemical characterization of the cellular infiltrate in discoid lupus erythematosus. BioScience Trends, 5: 83-88, 2011.

255.  Arakawa H, Jinnin M, Muchemwa FC, Makino T, Kajihara I, Makino K, Honda N, Sakai K, Fukushima S, Ihn H.  Adiponectin expression is decreased ininvolved skin and sera of diffuse cutaneous scleroderma patients. Exp Dermatol, 20: 764-766, 2011.

256.  Masuguchi S, Jinnin M, Fukushima S, Makino T, Sakai K, Inoue Y, Igata T, Ihn H.  The expression of HER-2 in extramammary Paget’s disease. BioScience Trends, 5: 151-155, 2011.

257.  Kuwata N, Makino T, Inoue Y, Ihn H.  Expression pattern of VEGF-1, -2, -3, and D2-40 protein in the skin of patients with systemic sclerosis. Eur J Dermatol, 21: 490-494, 2011.

258.  Maekawa T, Jinnin M, Ihn H.  The expression levels of thrombospondin-1 in dermatofibroma and dermatofibrosarcoma protuberans. Eur J Dermatol, 21: 534-538, 2011.

259.  Ichihara A, Jinnin M, Yamane K, Fujisawa A, Sakai K, Masuguchi S, Fukushima S, Maruo K, Ihn H.  micro-RNA mediated keratinocyte hyperproliferation in psoriasis. Br J Dermatol, 165: 1003-1010, 2011.

260.  Yamada M, Sakai K, Hayashi M, Hozumi Y, Abe Y, Kawaguchi M, Ihn H, Suzuki T. Oculocutaneous Albinism Type 3: A Japanese girl with novel mutations in TYRP1 gene. J Dermatol Sci, 64: 217-222, 2011.

261.  Jinnin M, Fukushima S, Masuguchi S, Tanaka H, Kawashita Y, Ishihara T, Ihn H.  Evaluation of usefulness of 3D views for clinical photography. BioScience Trends, 5: 211-216, 2011.

262.  Aoi J, Endo M, Kadomatsu T, Miyata K, Nakano M, Horiguchi H, Ogata A, Odagiri H, Yano M, Araki K, Jinnin M, Ito T, Hirakawa S, Ihn H, Oike Y. Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. Cancer Res, 71:7502-7512, 2011.

263.  Kajihara I, Jinnin M, Makino T, Toihata-Yonemitsu A, Sakai K, Masuguchi S, Fukushima S, Ihn H.  Clinical significance of cobble stone appearance on the skin of patients with systemic sclerosis. J Eur Acad Dermatol Venereol, 26: 123-125, 2012.

264.  Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y, Kuwana M, Muro Y, Ogawa F, Sasaki T, Takahashi H, Tanaka S, Takehara K, Sato S.  Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with systemic sclerosis: a multicenter prospective observational study. Rheumatology, 51:129-133, 2012.

265.  Namikawa K, Yamazaki N, Nakai Y, Ihn H, Tomita Y, Uhara H, Takenouchi T, Kiyohara Y, Moroi Y, Yamamoto Y, Otsuka F, Kamiya H, Iizuka H, Hatta N, Kadono T.  Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: A multi-institutional study of 450 patients in Japan. J Dermatol, 39: 130-137, 2012.

266.  Tomita M, Kadono T, Yazawa N, Kawashima T, Tamaki Z, Ashida R, Ohmatsu H, Asano Y, Sugaya M, Kubo M, Ihn H, Tamaki K, Sato S.  Serum levels of soluble CD21 in patients with systemic sclerosis. Rheumatol Int, 32: 317-321, 2012.

267.  Nakayama W, Jinnin M, Makino K, Kajihara I, Makino

Address
  • 27 Old Gloucester street,
    London United kindom,WCIN3AX.
Contact Us
License
Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.
© 2018. Vagus Inprosys All right reserved.